{
  "symbol": "GILD",
  "year": 2022,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.0708,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.287
  },
  "top_positive": [
    {
      "sent": "2004 Equity Incentive Plan, amended and restated May 10, 2017 (12) 10.3* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018) (13) 10.4* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (14) 10.5* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019) (15) 10.6* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020) (16) 10.7* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021) 10.8*,** Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year ves",
      "score": 0.9907
    },
    {
      "sent": "FAIR VALUE MEASUREMENTS We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: \u2022 Level 1 inputs include quoted prices in active markets for identical assets or liabilities; \u2022 Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and \u2022 Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability.",
      "score": 0.9852
    },
    {
      "sent": "Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets: (in millions) March 31, 2022 December 31, 2021 Cash and cash equivalents $ 2,360 $ 3,661 Prepaid and other current assets 692 885 Other long-term assets 1,286 1,197 Total $ 4,337 $ 5,743 Other Equity Securities Equity method investments and other equity investments without readily determinable fair values were $ 375 million and $ 338 million as of March\u00a031, 2022 and December\u00a031, 2021, respectively, and were included in Other long-term assets on our Condensed Consolidated Balance Sheets.",
      "score": 0.9848
    }
  ],
  "top_negative": [
    {
      "sent": "Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.",
      "score": -0.91
    },
    {
      "sent": "Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.",
      "score": -0.91
    },
    {
      "sent": "Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.",
      "score": -0.91
    }
  ],
  "forward_snippets": [
    "We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.",
    "Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets: (in millions) March 31, 2022 December 31, 2021 Cash and cash equivalents $ 2,360 $ 3,661 Prepaid and other current assets 692 885 Other long-term assets 1,286 1,197 Total $ 4,337 $ 5,743 Other Equity Securities Equity method investments and other equity investments without readily determinable fair values were $ 375 million and $ 338 million as of March\u00a031, 2022 and December\u00a031, 2021, respectively, and were included in Other long-term assets on our Condensed Consolidated Balance Sheets.",
    "We believe the \u2019830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir.",
    "We believe that the amended EP \u2019190 patent claims are invalid.",
    "We believe that the likelihood of a material adverse outcome in this matter is remote."
  ],
  "curated_text": "Symbol: GILD. Year: 2022. Period: Q3. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: 2004 Equity Incentive Plan, amended and restated May 10, 2017 (12) 10.3* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018) (13) 10.4* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (14) 10.5* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019) (15) 10.6* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020) (16) 10.7* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021) 10.8*,** Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year ves FAIR VALUE MEASUREMENTS We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: \u2022 Level 1 inputs include quoted prices in active markets for identical assets or liabilities; \u2022 Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and \u2022 Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets: (in millions) March 31, 2022 December 31, 2021 Cash and cash equivalents $ 2,360 $ 3,661 Prepaid and other current assets 692 885 Other long-term assets 1,286 1,197 Total $ 4,337 $ 5,743 Other Equity Securities Equity method investments and other equity investments without readily determinable fair values were $ 375 million and $ 338 million as of March\u00a031, 2022 and December\u00a031, 2021, respectively, and were included in Other long-term assets on our Condensed Consolidated Balance Sheets. Top negative sentences: Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts. Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts. Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts. Forward-looking snippets: We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets: (in millions) March 31, 2022 December 31, 2021 Cash and cash equivalents $ 2,360 $ 3,661 Prepaid and other current assets 692 885 Other long-term assets 1,286 1,197 Total $ 4,337 $ 5,743 Other Equity Securities Equity method investments and other equity investments without readily determinable fair values were $ 375 million and $ 338 million as of March\u00a031, 2022 and December\u00a031, 2021, respectively, and were included in Other long-term assets on our Condensed Consolidated Balance Sheets. We believe the \u2019830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. We believe that the amended EP \u2019190 patent claims are invalid. We believe that the likelihood of a material adverse outcome in this matter is remote."
}